Hospital Universitario Ramón y Cajal

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial (2025) Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, et al. Journal article ESPEN guideline on clinical nutrition and hydration in geriatrics Guide pratique de la Société européenne de nutrition clinique: nutrition clinique et hydratation en gériatrie (2024) Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Hooper L, Kiesswetter E, Maggio M, et al. Journal article Critical outcomes to be included in the Core Outcome Set for nutritional intervention studies in older adults with malnutrition or at risk of malnutrition: a modified Delphi Study (2024) Mendonça N, Avgerinou C, Çavdar S, Cederholm T, Cruz-Jentoft AJ, Torbahn G, Sieber C, et al. Journal article A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 (2024) Hughes BG, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, et al. Journal article Clinical Characteristics of Anti-synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project (2024) Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, Dourado E, et al. Journal article The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study (2023) Oddo M, Taccone FS, Petrosino M, Badenes R, Blandino-Ortiz A, Bouzat P, Caricato A, et al. Journal article A Core Outcome Set for nutritional intervention studies in older adults with malnutrition and those at risk: a study protocol (2023) Visser M, Mendonça N, Avgerinou C, Cavdar S, Cederholm T, Cruz-Jentoft AJ, Kiesswetter E, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study (2022) Dey M, Naveen R, Nikiphorou E, Sen P, Saha S, Lilleker JB, Agarwal V, et al. Journal article, Letter Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial (2022) González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, et al. Journal article